NCT03462043WithdrawnPhase 3
A Pivotal, Open-Label, Randomized, Crossover Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Withdrawn
- Sponsor
- NeuroDerm Ltd.
- Locations
- 2
- Primary Endpoint
- Bioavailability
Study Overview
Brief Summary
This study will assess the relative bioavailability of s.c. infused ND0612 versus jejunally infused CLES in patients with advanced PD.
Detailed Description
This study will be an open-label, randomized, crossover study to assess the relative bioavailability of s.c. infused ND0612 versus jejunally infused CLES in patients with advanced PD.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 30 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with Advanced PD treated with LD/CD at a dose of at least 800 mg LD
- •Female patients must have a negative pregnancy test at screening and at admission.
- •Patients must have a body mass index (BMI) within the range of 18.5 - 35 kg/m2, where BMI = body weight (kg) / height (m2) at screening.
- •Must be willing and able to communicate and participate in the whole study.
- •Must provide written informed consent.
- •Must agree to use an adequate method of contraception (per local independent ethics committee requirements).
- •Area of administration to be evaluable for local skin reaction (normal skin without skin burns, scars or large tattoos in the area of administration
Exclusion Criteria
- •Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the patient unsuitable for study entry or potentially unable to complete all aspects of the study.
- •Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) at the screening visit.
- •Patients with a history of drug abuse or alcoholism within the past 12 months prior to screening or positive drugs of abuse or alcohol test result at the screening visit and/or on admission.
- •Clinically significant electrocardiogram (ECG) rhythm abnormalities.
- •Renal or liver dysfunction that may alter drug metabolism including: serum creatinine >1.5 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN), total serum bilirubin >2.5 mg/dL.
- •Psychiatric, neurological or behavioral disorders that may interfere with the conduct or interpretation of the study, including dementia, or patients who are considered to be violent or at suicidal risk by the Investigator.
- •Blood loss of greater than 500 mL within the previous 3 months prior to first dosing.
- •use of any medication from the prohibited concomitant therapies
Arms & Interventions
Sequence A
Active Comparator
Intervention: CLES (Combination Product)
Sequence A
Active Comparator
Intervention: ND0612 (Combination Product)
Sequence B
Active Comparator
Intervention: ND0612 (Combination Product)
Sequence B
Active Comparator
Intervention: CLES (Combination Product)
Sequence C
Active Comparator
Intervention: CLES (Combination Product)
Sequence D
Active Comparator
Intervention: CLES (Combination Product)
Sequence D
Active Comparator
Intervention: ND0612 (Combination Product)
Sequence C
Active Comparator
Intervention: ND0612 (Combination Product)
Outcomes
Primary Outcomes
Bioavailability
Time Frame: 6-7 days
To assess relative bioavailability of levodopa (LD) administered as ND0612, infused subcutaneously (s.c.), versus LD administered as carbidopa-levodopa enteral suspension (CLES)
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple DoseObesityNCT03586843Janssen Research & Development, LLC52
Completed
Phase 1
A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy ParticipantsHealthyNCT04667052Janssen Research & Development, LLC43
Completed
Phase 1
A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy ParticipantsHealthyNCT03952507Janssen Research & Development, LLC18
Completed
Phase 1
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol CypionateContraceptionNCT03443089Galeno Desenvolvimento de Pesquisas Clínicas24
Completed
Phase 1
Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy ParticipantsHealthyNCT02231489Janssen Research & Development, LLC12